Elevian, an emerging biotech company, has signed a research and development collaboration with United States-based Insilico Medicine to produce oral medications targeting the GDF11 pathway and associated targets, it was reported yesterday.
The partnership will utilise Insilico's generative adversarial networks and reinforcement learning AI technologies to discover novel small molecules that target the GDF11 pathway, which has been demonstrated to play an important role in aging and age-related disease.
Agenus is to use Selexis' technology to produce therapeutic proteins. In order to succeed in this endeavour, both firms will use state-of-the-art techniques in AI-enabled drug discovery. Based on biological and structural target data from Elevian, Insilico will identify small molecules that produce the intended biological actions utilising deep learning technology.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study